"This is clinical development so there are going to be some setbacks."– Gil Van Bokkelen, CEO of Athersys Inc. and chairman of the Alliance for Regenerative Medicine"You can see a slight change in subject one's pulse here. But I can tell you, his pulse was substantially lower than my own pulse when this vector was going in."– Amit Nathwani, investigator on a trial testing Factor IX gene therapy for hemophilia B, describing monitoring patients for adverse reaction during infusions"If programs stumble, jobs are at stake."